CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 200 target
Drug / intervention
Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cellsbiological
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Advanced ovarian cancer or other cancers with claudin-6 expression
  • ✓Life expectancy greater than 12 weeks
  • ✓Adequate heart, lung, liver, kidney function
  • ✓Autologous transduced NK cells with ≥20% CAR expression (Claudin6, GPC3, Mesothelin, or AXL)
Key exclusion· 10
  • ✕Prior gene therapy
  • ✕Tumor size >25 cm
  • ✕Severe viral infection (HBV, HCV, HIV, etc.)
  • ✕Known HIV positivity

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05410717
NCT05410717Phase 1RecruitingOn TrackUpdated 24mo ago
Long Recruiting
CompareCT.gov

Phase I Trial to Evaluate Safety and Preliminary Efficacy of CLDN6/GPC3/Mesothelin/AXL-CAR-NK in Patients With CLDN6/GPC3/Mesothelin/AXL-positive Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Jun 8, 2022·Updated Jun 25, 2024

In Brief

A Phase 1 clinical trial evaluating Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells for Stage IV Ovarian Cancer and 3 related conditions. Currently recruiting, targeting 200 participants across 1 site.

Detailed Summary

This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent, CAR NK
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20232024202520262027202820292030203120322033203420352036
First PostedJun 8, 2022
Enrollment StartJun 1, 2022
Primary CompletionJun 1, 2030
Study CompletionMay 31, 2036
TodayJul 1, 2026
Enrollment to primary: 8 yearsPosted 4.1 years agoPrimary completion in 3.9 years

Interventions

Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cellsbiological

Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients. In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy.